What is HC Wainwright’s Estimate for ATNM FY2026 Earnings?

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) – Investment analysts at HC Wainwright cut their FY2026 earnings per share (EPS) estimates for shares of Actinium Pharmaceuticals in a research note issued on Tuesday, March 31st. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of ($1.09) for the year, down from their previous forecast of ($0.75). The consensus estimate for Actinium Pharmaceuticals’ current full-year earnings is ($1.41) per share. HC Wainwright also issued estimates for Actinium Pharmaceuticals’ FY2027 earnings at ($0.80) EPS and FY2028 earnings at ($0.86) EPS.

Separately, Stephens restated an “overweight” rating and issued a $5.00 price target on shares of Actinium Pharmaceuticals in a research report on Tuesday. Two analysts have rated the stock with a Buy rating, According to data from MarketBeat, Actinium Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $4.50.

Actinium Pharmaceuticals Stock Performance

NYSE ATNM opened at $0.98 on Thursday. The company has a market capitalization of $30.76 million, a P/E ratio of -0.71 and a beta of -0.21. Actinium Pharmaceuticals has a one year low of $0.95 and a one year high of $1.95. The stock has a 50 day moving average price of $1.13 and a 200-day moving average price of $1.35.

Institutional Investors Weigh In On Actinium Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in Actinium Pharmaceuticals by 0.9% during the third quarter. Vanguard Group Inc. now owns 1,384,543 shares of the company’s stock worth $2,215,000 after acquiring an additional 12,703 shares during the last quarter. Mayport LLC bought a new stake in shares of Actinium Pharmaceuticals in the 3rd quarter valued at approximately $35,000. AM Investment Strategies LLC purchased a new position in shares of Actinium Pharmaceuticals in the 4th quarter worth approximately $40,000. Bank of America Corp DE boosted its holdings in shares of Actinium Pharmaceuticals by 76.6% in the 4th quarter. Bank of America Corp DE now owns 78,767 shares of the company’s stock worth $99,000 after purchasing an additional 34,176 shares during the period. Finally, AQR Capital Management LLC increased its position in shares of Actinium Pharmaceuticals by 278.6% during the 1st quarter. AQR Capital Management LLC now owns 63,249 shares of the company’s stock valued at $102,000 after purchasing an additional 46,545 shares during the last quarter. 27.50% of the stock is owned by institutional investors.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on the development of targeted radiopharmaceutical therapies for patients with hematologic malignancies. The company’s proprietary technology platform combines monoclonal antibodies with radioisotopes to deliver highly potent, cell‐killing radiation directly to cancer cells while sparing healthy tissues. Actinium’s lead product candidate, Iomab‐B, is being evaluated as a conditioning regimen for older patients with acute myeloid leukemia (AML) who are ineligible for standard bone marrow transplants.

In addition to Iomab‐B, Actinium’s pipeline includes Actimab‐A, an anti‐CD33 antibody labeled with the radioisotope bismuth‐213 for the treatment of relapsed or refractory AML.